BNC210 (also known as IW-2143 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor,[1] by Bionomics Limited.

[3] It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.

In December 2012, IW-2143 begun undergoing phase I clinical trials in the United States,[5] but in November 2014, was released back to Bionomics in a mutual agreement.

[12] With respect to fMRI data, the drug had a more pronounced effect at the low dose, reportedly on par with Lorazepam, while the high-dose was most similar to Placebo.

The study included only 24 participants, in 4 arms, so drawing major conclusions from the paper is not wise, but it at least provides additional evidence of possible efficacy.